Earnings call Dr. Lal PathLabs reported 10.7% YoY revenue growth and 19.3% PAT growth in Q3 FY25, despite no price increases. The company is executing a multi-pronged strategy of geographic expansion, ...

Diagnostics services company Dr Lal Path Labs on Friday announced an interim dividend of Rs 7 per equity share for the financial year 2025-26. The company also declared a 1:1 bonus issue where it will ...

Dr Lal Path Labs Dividend 2026: Dr Lal Path Labs on Thursday (April 30) declared its Q4 quarterly results for financial year 2025-26. Along with the quarterly earnings, the BSE 500 company also ...

(Reuters) - India's Dr Lal Path Labs reported a 19% jump in its third-quarter profit on Thursday, led by continued demand for its bundle test offerings, sending its shares 3% higher. The company's ...

Shares of Dr Lal Path Labs surged in morning trade on Monday after the diagnostics company reported better-than-expected June quarter results. The stock climbed as much as 7.55 percent during the ...

Bengaluru: Dr. Lal Path Labs reported a ‍lower third-quarter profit on Friday after taking a one-time charge ⁠linked to India's new labour code, despite strong demand for its bundled test packages.

India's Dr Lal PathLabs posts higher first-quarter profit on healthy demand for tests Indian diagnostics firm Dr Lal PathLabs on Friday reported a rise in first-quarter profit, boosted by sustained ...

Dr. Lal Path Labs shares have shown a steady upward trend across most timeframes, outperforming the broader Nifty 500 and reflecting strong investor interest around the company’s growth outlook and ...

(Reuters) - Dr. Lal PathLabs, India's top diagnostics firm by revenue, reported a bigger-than-expected second-quarter profit on Wednesday, driven by continued demand and a rising awareness for health ...

Earnings call Dr. Lal PathLabs delivered robust Q2 FY26 results with revenue up 10.7% YoY to INR 731 crore and PAT rising 16.4% YoY, driven by strong operational execution and volume growth.